Two friends from Philadelphia are revolutionizing the way that the world finds antidotes for bacterial and viral infections.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at firstname.lastname@example.org.
Brian Frezza and Daniel Jerome Kleinbaum’s Emerald Cloud Laboratory has innovated a testing base for new drugs which it claims to be faster and much less expensive than the technologies currently in use. As its name implies, the new test is cloud based, meaning that the tools and technology that it provides are hosted on the Internet through the company’s servers, and can be accessed by users anywhere in the world without the need for acquiring and installing software on every individual computer that utilizes it.
The cloud based computers will be able to analyze molecules affected by bacteria or virus, which a user will upload to the system. The ECL’s web interface will let users remotely access every part of an experiment as if he or she were actually in the firm’s lab standing in front of the instruments.
This will spare local medical facilities the great expense of owning and maintaining their own equipment, as well as do away with the time that it takes to send samples to a remote lab for analysis.
A full suite of visualization, analysis, and simulation tools is provided to ECL users, all accessible through a web browser. The ECL offers more than 1, 000 independent functions for data manipulation and is powered by the Wolfram Language, which offers an additional 3, 500 plus functions for visualizing and manipulating scientific information.
The ECL is currently in private alpha testing, with plans for a larger beta rollout to begin in early 2015.
Emerald Cloud Laboratory was founded by Emerald Therapeutics, a venture-backed biotechnology company based in Menlo Park, California. The company was started in 2010 by its co-CEOs, two life-long friends Brian Frezza and Daniel Jerome Kleinbaum (both Ph.D. scientists), and is staffed by top, international scientists and engineers. The company originally developed the ECL as an internal product built to streamline research efforts, ensure reproducibility, and provide greater leverage for Emerald’s scientists. Now, Emerald is bringing the ECL to the world to provide leaner, more reproducible scientific research to everyone.
Emerald has raised $13.5 million over two funding rounds, from Founders Fund, PayPal Co-Founder Max Levchin, and Schooner Capital.
Brian M. Frezza spearheads Emerald’s therapeutic research effort and is the lead architect of Symbolic Lab Language, a programming language deployed at Emerald for conducting and managing data surrounding wet lab experiments by computer. He completed his PhD in Chemical Biology at The Scripps Research Institute working on DNA nanotechnology.
Daniel Jerome Kleinbaum has a Ph.D. in Chemistry and a B.S. in Biological Sciences.